Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
07 2022
Historique:
received: 03 02 2022
accepted: 14 06 2022
revised: 15 07 2022
pubmed: 6 7 2022
medline: 20 7 2022
entrez: 5 7 2022
Statut: epublish

Résumé

The limited development of broadly neutralizing antibodies (BnAbs) during HIV infection is classically attributed to an inadequate B-cell help brought by functionally impaired T follicular helper (Tfh) cells. However, the determinants of Tfh-cell functional impairment and the signals contributing to this condition remain elusive. In the present study, we showed that PD-L1 is incorporated within HIV virions through an active mechanism involving p17 HIV matrix protein. We subsequently showed that in vitro produced PD-L1high but not PD-L1low HIV virions, significantly reduced Tfh-cell proliferation and IL-21 production, ultimately leading to a decreased of IgG1 secretion from GC B cells. Interestingly, Tfh-cell functions were fully restored in presence of anti-PD-L1/2 blocking mAbs treatment, demonstrating that the incorporated PD-L1 proteins were functionally active. Taken together, the present study unveils an immunovirological mechanism by which HIV specifically exploits the regulatory potential of PD-L1 to suppress the immune system during the course of HIV infection.

Identifiants

pubmed: 35788752
doi: 10.1371/journal.ppat.1010673
pii: PPATHOGENS-D-22-00210
pmc: PMC9286290
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1010673

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Nat Biotechnol. 2012 Sep;30(9):858-67
pubmed: 22902532
Immunity. 2013 Oct 17;39(4):758-69
pubmed: 24035365
J Virol. 1997 May;71(5):3588-96
pubmed: 9094631
J Immunol. 2005 Apr 15;174(8):4779-88
pubmed: 15814703
J Exp Med. 2014 Aug 25;211(9):1905-18
pubmed: 25113973
Virology. 1996 Apr 15;218(2):372-81
pubmed: 8610464
Cell Res. 2018 Aug;28(8):862-864
pubmed: 29959401
Immunol Rev. 2019 Nov;292(1):149-163
pubmed: 31883174
Microbiol Mol Biol Rev. 1998 Dec;62(4):1171-90
pubmed: 9841669
J Virol. 1997 Mar;71(3):1922-30
pubmed: 9032323
J Virol. 2015 Jan;89(1):323-36
pubmed: 25320314
Nature. 1993 Mar 25;362(6418):355-8
pubmed: 8455722
Cytometry A. 2011 Feb;79(2):167-74
pubmed: 21265010
BMC Biol. 2016 Jun 23;14:50
pubmed: 27338237
Nat Med. 2016 Jul;22(7):754-61
pubmed: 27239760
J Extracell Vesicles. 2020 Jan 7;9(1):1710899
pubmed: 32002173
PLoS Pathog. 2016 Jan 14;12(1):e1005369
pubmed: 26766578
AIDS. 1996 Dec;10(14):1611-20
pubmed: 8970680
AIDS Res Hum Retroviruses. 1993 Nov;9(11):1157-65
pubmed: 8312057
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
PLoS Pathog. 2012;8(8):e1002840
pubmed: 22916009
Sci Immunol. 2017 May 12;2(11):
pubmed: 28763793
Oncotarget. 2015 Feb 20;6(5):3280-91
pubmed: 25682864
Nat Med. 2013 Apr;19(4):494-9
pubmed: 23475201
J Virol. 2004 Nov;78(21):11916-25
pubmed: 15479832
Clin Cancer Res. 2018 Feb 15;24(4):896-905
pubmed: 29233903
J Infect Dis. 2005 Oct 1;192(7):1265-8
pubmed: 16136471
J Virol. 2008 Jan;82(2):1021-33
pubmed: 17989173
J Virol. 2002 Feb;76(3):1004-14
pubmed: 11773376
J Exp Med. 2006 Oct 2;203(10):2281-92
pubmed: 16954372
Nat Rev Immunol. 2004 May;4(5):336-47
pubmed: 15122199
J Virol. 2007 Apr;81(7):3272-84
pubmed: 17229706
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
Annu Rev Immunol. 2016 May 20;34:635-59
pubmed: 27168247
Front Immunol. 2018 Jul 11;9:1597
pubmed: 30050534
Front Immunol. 2018 Feb 05;9:144
pubmed: 29459864
Nature. 2006 Sep 21;443(7109):350-4
pubmed: 16921384
J Exp Med. 2013 Jan 14;210(1):143-56
pubmed: 23254284
J Biol Chem. 2003 Dec 26;278(52):52347-54
pubmed: 14561735
Nat Med. 2006 Oct;12(10):1198-202
pubmed: 16917489
Cytometry A. 2017 Jan;91(1):39-47
pubmed: 27632576
Immunity. 2018 Aug 21;49(2):264-274.e4
pubmed: 30076099
PLoS Pathog. 2019 Jul 22;15(7):e1007918
pubmed: 31329640
J Immunol. 2007 Aug 1;179(3):1979-87
pubmed: 17641065
J Biol Chem. 2001 Mar 2;276(9):6359-69
pubmed: 11096063
Clin Dev Immunol. 2012;2012:485781
pubmed: 22548114
Science. 1992 Dec 18;258(5090):1935-8
pubmed: 1470916
Immunol Rev. 2017 Jan;275(1):49-61
pubmed: 28133798
J Virol. 2006 Sep;80(18):9039-52
pubmed: 16940516
Blood. 2011 May 5;117(18):4805-15
pubmed: 21398582
Sci Rep. 2019 Aug 27;9(1):12392
pubmed: 31455818
Ann Surg Oncol. 2019 Oct;26(11):3745-3755
pubmed: 31087180
Nat Cell Biol. 2019 Apr;21(4):452-461
pubmed: 30936472
Nanoscale. 2019 Mar 28;11(13):6036-6044
pubmed: 30869094
Lung Cancer. 2020 Oct;148:1-11
pubmed: 32768804
Viruses. 2019 Jan 20;11(1):
pubmed: 30669528
Mol Ther. 2017 Jul 5;25(7):1665-1675
pubmed: 28284981
J Gen Virol. 2007 Sep;88(Pt 9):2568-2573
pubmed: 17698668
J Virol. 2005 Dec;79(23):14595-605
pubmed: 16282459
J Virol. 1999 May;73(5):3603-7
pubmed: 10196251
J Virol. 2003 Nov;77(22):12299-309
pubmed: 14581566
Science. 2013 Sep 13;341(6151):1199-204
pubmed: 24031012
PLoS Pathog. 2016 Jan 07;12(1):e1005349
pubmed: 26741490
J Virol. 2000 Apr;74(7):3264-72
pubmed: 10708443
PLoS Pathog. 2013;9(7):e1003423
pubmed: 23853580
Clin Cancer Res. 2017 Aug 15;23(16):4843-4854
pubmed: 28400428
Genome Med. 2020 Sep 28;12(1):83
pubmed: 32988398
PLoS Pathog. 2014 Sep 25;10(9):e1004380
pubmed: 25255144
PLoS Pathog. 2019 Jan 17;15(1):e1007429
pubmed: 30653605
Medicine (Baltimore). 2020 May;99(20):e20065
pubmed: 32443313
Immunol Lett. 2018 Nov;203:70-79
pubmed: 30236481
Int J Mol Sci. 2020 Oct 22;21(21):
pubmed: 33105908
J Clin Invest. 2010 Jul;120(7):2508-15
pubmed: 20551512
Front Immunol. 2018 Apr 30;9:738
pubmed: 29760691
Nature. 2014 May 1;509(7498):55-62
pubmed: 24590074
J Immunol. 2015 Apr 15;194(8):3873-82
pubmed: 25780040
PLoS Pathog. 2016 Jul 14;12(7):e1005661
pubmed: 27415828
Sci Rep. 2016 Apr 18;6:24436
pubmed: 27087234
Front Immunol. 2017 Nov 30;8:1698
pubmed: 29250073
J Virol. 2015 Dec 09;90(4):1858-71
pubmed: 26656693
Cell. 2019 Apr 4;177(2):414-427.e13
pubmed: 30951669
Curr Opin Immunol. 2004 Jun;16(3):328-36
pubmed: 15134782
Nat Rev Immunol. 2015 Mar;15(3):185-9
pubmed: 25677493
Nat Med. 2012 Nov;18(11):1688-92
pubmed: 23086475
Eur J Immunol. 2006 Oct;36(10):2658-70
pubmed: 16981182
AIDS Res Hum Retroviruses. 1995 Dec;11(12):1433-9
pubmed: 8679286
J Exp Med. 2008 Nov 24;205(12):2763-79
pubmed: 19001139

Auteurs

Olivia Munoz (O)

Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Riddhima Banga (R)

Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Rachel Schelling (R)

Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Francesco Andrea Procopio (FA)

Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Andrea Mastrangelo (A)

Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Pauline Nortier (P)

Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Khalid Ohmiti (K)

Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Jean Daraspe (J)

Electron Microscopy Facility, University of Lausanne, Lausanne, Switzerland.

Matthias Cavassini (M)

Services of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Craig Fenwick (C)

Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Laurent Perez (L)

Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Matthieu Perreau (M)

Services of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH